ETBX-011

BIOLOGICAL18 trials

Sponsors

NantCell, Inc., ImmunityBio, Inc.

Conditions

Breast CancerColon CancerColorectal CancerColorectal Cancer MetastaticHead and Neck Squamous Cell CarcinomaHepatocellular Carcinoma Non-resectableHepatocellular Carcinoma RecurrentLung Cancer

Phase 1

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

TerminatedNCT03127098

NantCell, Inc.Breast Cancer, Colon Cancer, Lung Cancer +3

Start: 2017-06-26End: 2017-12-07Updated: 2024-08-06

QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

TerminatedNCT03136406

ImmunityBio, Inc.Pancreatic Cancer

Start: 2017-08-11End: 2019-11-01Updated: 2024-06-11

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

WithdrawnNCT03167177

ImmunityBio, Inc.Melanoma

Start: 2017-12-31End: 2021-12-28Updated: 2025-02-21

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

WithdrawnNCT03169738

ImmunityBio, Inc.Non-small Cell Lung Cancer

Start: 2018-02-28End: 2021-12-28Updated: 2025-02-21

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

WithdrawnNCT03169777

ImmunityBio, Inc.Colorectal Cancer

Start: 2018-08-31End: 2021-12-28Updated: 2025-02-21

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

WithdrawnNCT03169764

ImmunityBio, Inc.Head and Neck Squamous Cell Carcinoma

Start: 2017-12-31End: 2021-12-28Updated: 2025-02-24

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

WithdrawnNCT03175666

ImmunityBio, Inc.Triple Negative Breast Cancer

Start: 2017-12-31End: 2021-12-28Updated: 2025-02-21

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

WithdrawnNCT03197571

ImmunityBio, Inc.Urothelial Carcinoma

Start: 2017-12-31End: 2021-12-28Updated: 2025-02-21

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

TerminatedNCT03329248

ImmunityBio, Inc.Pancreatic Cancer

Start: 2017-11-06End: 2019-11-01Updated: 2024-12-12

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

TerminatedNCT03387098

ImmunityBio, Inc.Pancreatic Cancer

Start: 2017-12-28End: 2019-01-15Updated: 2024-05-22

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

TerminatedNCT03387111

ImmunityBio, Inc.Squamous Cell Carcinoma

Start: 2018-01-09End: 2021-01-11Updated: 2024-08-05

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

TerminatedNCT03387085

ImmunityBio, Inc.Triple Negative Breast Cancer

Start: 2018-03-19End: 2024-01-16Updated: 2024-08-09

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

WithdrawnNCT03563170

ImmunityBio, Inc.Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent

Start: 2018-05-25End: 2019-08-23Updated: 2021-03-18

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

TerminatedNCT03563157

ImmunityBio, Inc.Colorectal Cancer Metastatic, mCRC

Start: 2018-09-28End: 2019-08-21Updated: 2024-12-11

QUILT-3.080: NANT Pancreatic Cancer Vaccine

TerminatedNCT03586869

ImmunityBio, Inc.Pancreatic Cancer

Start: 2018-07-17End: 2019-08-01Updated: 2024-08-27

Phase 2

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

WithdrawnNCT03554109

ImmunityBio, Inc.Triple Negative Breast Cancer (TNBC)

Start: 2018-09-30End: 2022-02-09Updated: 2025-02-21

QUILT-3.088: NANT Pancreatic Cancer Vaccine

WithdrawnNCT03563144

ImmunityBio, Inc.Metastatic Pancreatic Cancer

Start: 2018-08-31End: 2022-02-09Updated: 2025-02-21

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

WithdrawnNCT03574649

ImmunityBio, Inc.Non Small Cell Lung Cancer

Start: 2018-06-30End: 2018-08-22Updated: 2025-02-21

Related Papers

Overall survival in patients with metastatic or locally advanced pancreatic cancer following chemoradiation with novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.

Journal of Clinical Oncology2023-01-246 citations

Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T-cell therapy in patients with third line or greater TNBC.

Journal of Clinical Oncology2019-05-204 citations

Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer.

Journal of Clinical Oncology2019-05-202 citations

Correlation between circulating cell-free RNA biomarkers and response during combination immunotherapy in previously refractory metastatic TNBC patients.

Journal of Clinical Oncology2019-05-201 citations

NANT cancer vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer.

Journal of Clinical Oncology2019-01-298 citations